secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0000875045-23-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen posts Q1 GAAP EPS $2.67, non-GAAP $3.40; reaffirms FY23 guidance; multiple regulatory milestones
--------------------------------------------------------------------------------

- Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).
- LEQEMBI Alzheimer's drug: FDA Accelerated Approval, traditional filing Priority Review; PDUFA July 6, 2023.
- Zuranolone depression NDA accepted with Priority Review; PDUFA Aug 5, 2023.
- Tofersen SOD1-ALS PDUFA date April 25, 2023; Advisory Committee backed surrogate endpoint.
- Appointed Chuck Triano (IR) and Adam Keeney (Corporate Dev); cost optimization program initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/0000875045-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000012/biib-20230425.htm
  HTML page:      https://secwatch.observer/filing/0000875045-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer